NYSE:UNH

UnitedHealth Group Inc (UNH)

424.72
-3.47 (0.81%)
as of Jul 8, 2026, 10:00:07 pm Market Open.
288 watching
0
Investor Insights
star iconJul 8, 2026, 12:00 am

This summary was created by AI, based on 41 opinions in the last 12 months.

UnitedHealth Group Inc (UNH) faces a complex set of challenges and opportunities as experts express mixed sentiments about its future. On one hand, there is optimism regarding its recovery potential, driven by leadership changes, historical success, and potential growth in earnings as medical costs stabilize. However, many analysts are concerned about sustained pressures from regulatory scrutiny, rising healthcare costs, and shifts in Medicare policies. While some see it as a defensive play with the potential for significant upside, others caution against investing due to a reputation for volatility and uncertain future prospects. Analysts point to a strong reliance on US federal funding and highlight the impact of broader economic factors affecting the healthcare sector overall.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Undervalued
review icon
Similar
CVS
TOP PICK
No other US company comes close to their scale and size. Mix of services produces steady and reliable sales. Great technical chart for 10 years. Beat expectation last quarter. Expects earnings growth to top 14% over the next few years. Dividend will continue to grow. Yield is 1.45%. (Analysts’ price target is $441.36)
PAST TOP PICK
(A Top Pick Jan 17/20, Up 14%) An easy hold. Great visibility. Managed care. Commercial health insurance, plus one of the key administrators of Medicare and Medicaid. Enjoys bipartisan support. Underlying businesses are doing great.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Aug 25/20, Up 5.69%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with UNH has triggered our $330 stop level. Given the technical breakdown that points to further potential downward moves, we are recommending covering the entire position at this time. We will consider it for future acquisition at lower levels.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Aug 25/20, Up 15.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with UNH is moving well. We are recommending to trail up the stop to $330, which should all but guarantee a minimum return of 10%.
PAST TOP PICK
(A Top Pick Sep 28/20, Up 15%) Trying to be more proactive in getting patients treated and cutting costs. Encourages healthcare providers to be efficient. An ounce of prevention is worth a pound of cure.
HOLD
You have to endure a few really bad quarters before this bounces back. Don't chase it.
BUY

This stock should skate through a change in administration or even another Trump term. Americans are quite happy with private healthcare solutions. 180M Americans have some sort of private health. 75% are happy with this so it would probably not be disrupted in a large way. He prefers Anthem but there is no problem with UNH.

PAST TOP PICK
(A Top Pick Jul 17/19, Up 25%) Managed care in the past 7 election cycles outperformed the market post-US elections. UNH is one of the largest US health insurers, plus they have their networks of doctors and facilities, and they manage Medicare (a fast area of growth). Acquisitions have positioned them as dominant in managed care. This remains a top pick.
TOP PICK
He's sticking with it. You're buying the best in class. Some of their platforms receive bi-partisan support from Washington. Their Medicare business will see great growth in the next 3-4 years. They're vertically integrated. Pays a decent dividend at a decent valuation. He likes this managed care sector. (Analysts’ price target is $362.46)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Aug 25/20, Up 6.3%)Stockchase Research Editor: Michael O'Reilly Our TOP PICK in UNH has achieved analyst targets. We like the technical breakout and could see a test of $350 soon. We recommend moving the stop-loss from $280 up closer to the acquisition cost to $300.
TOP PICK
The dominant health insurance company in the US. It is the first one to integrate the pharmacy, benefits and insurance payer all into one. They are generating a lot of good will during COVID. (Analysts’ price target is $344.96)
BUY ON WEAKNESS
A very good company, but we're in a mean political season (the US election when health companies are politicians' targets). Though the stock has fallen, he'd wait until it hit $280 before stepping it with a first position.
COMMENT
AFAFD
WEAK BUY
An excellent health operator. But if this crisis continues, employment levels may remain very low which could impact UNH. But UNH has probably seen the worst of the pandemic and this is a blue-chip name. Will be fine after this crisis, which she sees passing one day.
BUY
Healthcare is one of his top 3 sectors in his portfolio, along with tech and communications. Concern about a Democrat sweep. With what's happened in the world, there will be a refocus on healthcare and health sciences. Long-term, demographics in its favour. Pretty good valuation at 22x, 12% earnings growth. Yield is about 1.6%.
Showing 166 to 180 of 287 entries